Soo Jung Kim

TL;DR: This work shows that programmed necrosis is activated in response to many chemotherapeutic agents and contributes to chemotherapy-induced cell death, and proposes that RIP3-deficient cancer patients may benefit from receiving hypomethylating agents to induce RIP3 expression prior to treatment with conventional Chemotherapeutics.

TL;DR: A previously undescribed function for NQO1 is shown in stabilizing HIF-1α, a master transcription factor of oxygen homeostasis that has been implicated in the survival, proliferation and malignant progression of cancers.

TL;DR: Findings indicate that vessel normalization by PI3K inhibitors restrained tumor growth and metastasis while improving chemotherapy by enhancing drug delivery into the tumor, suggesting that HS-173 may have a therapeutic value as an enhancer or an anticancer drug.

TL;DR: Investigation of the anticancer effects of a novel phosphatidylinositol 3-kinase α (PI3Kα) inhibitor in human NSCLC cell lines demonstrates that HS-173 exhibits anticancer activities, including the induction of apoptosis, by blocking the PI3K/Akt/mTOR pathway in human lung cancer cell lines, and suggests that this novel drug could potentially be used for targetedNSCLC therapy.

TL;DR: It is suggested that RT11-i and gemcitabine be viewed a potential combination treatment option for pancreatic cancer patients with KRAS mutation because of the synergistic anticancer activity shown.